NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1746-1596

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas ; volume:10 ; number:1 ; day:25 ; month:7 ; year:2015 ; pages:1-10 ; date:12.2015
Diagnostic pathology ; 10, Heft 1 (25.7.2015), 1-10, 12.2015

Creator: Uguen, Arnaud
Talagas, Matthieu
Costa, Sebastian
Samaison, Laura
Paule, Laure
Alavi, Zarrin
De Braekeleer, Marc
Le Marechal, Cédric
Marcorelles, Pascale

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13000-015-0359-0

URN: urn:nbn:de:101:1-2019112104055150540814

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Uguen, Arnaud
Talagas, Matthieu
Costa, Sebastian
Samaison, Laura
Paule, Laure
Alavi, Zarrin
De Braekeleer, Marc
Le Marechal, Cédric
Marcorelles, Pascale
SpringerLink (Online service)

Other Objects (12)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations

Variation of mutant allele frequency in NRAS Q61 mutated melanomas

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas

Related objects

Reset password